Heron Therapeutics
HRTX
161 hedge funds and large institutions have $331M invested in Heron Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 46 reducing their positions, and 18 closing their positions.
1,101% more call options, than puts
Call options by funds: $4.7M | Put options by funds: $391K
72% more capital invested
Capital invested by funds: $192M → $331M (+$139M)
56% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 18
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
7% more funds holding
Funds holding: 151 → 161 (+10)
4.15% more ownership
Funds ownership: 75.24% → 79.39% (+4.1%)
0% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$10.5M |
| 2 |
Millennium Management
New York
|
+$4.85M |
| 3 |
D.E. Shaw & Co
New York
|
+$3.53M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.52M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
-$8.28M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
-$2.17M |
| 3 |
Morgan Stanley
New York
|
-$1.82M |
| 4 |
MAM
Monaco Asset Management
Monaco
|
-$1.04M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$564K |
HRTX Hedge Fund Activity: Q1 2024 in Review
161 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2024, worth a combined $331M — up 72% from $192M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new HRTX positions and 18 closed out — a net gain of 10 holders — while 46 added to existing stakes and 46 trimmed.
The largest buyer was OrbiMed, adding an estimated $10.5M. The largest seller was Clearline Capital, cutting an estimated $8.28M.
- 161 institutional investors held Heron Therapeutics (HRTX) as of Q1 2024, up from 151 in Q4 2023.
- Funds reported $331M of Heron Therapeutics stock for Q1 2024, up 72% quarter-over-quarter.
- 28 funds opened new Heron Therapeutics positions in Q1 2024 and 18 closed out, a net change of +10 holders.
- The largest Heron Therapeutics buyer in Q1 2024 was OrbiMed, an estimated $10.5M added.
- The largest Heron Therapeutics seller in Q1 2024 was Clearline Capital, an estimated $8.28M sold.
Based on aggregated 13F filings for Q1 2024.